SCHEMBL20528875

SCHEMBL20528875

NCCN(CCN)C(=O)CCCCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 0.56
CYP2D6 P10635 1/20 0.56
LMNA P02545 4/20 0.54
BLM P54132 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
THRB P10828 2/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
PLG P00747 1/20 0.54
ALOX15 P16050 1/20 0.54
SLC6A2 P23975 1/20 0.54
RECQL P46063 1/20 0.54
SLC6A3 Q01959 1/20 0.54
TSHR P16473 2/20 0.52
GABRR3 A8MPY1 1/20 0.52
GABRP O00591 1/20 0.52
GABRD O14764 1/20 0.52
HDAC3 O15379 1/20 0.52
GABBR2 O75899 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20640381 0.96 LMNA (0.52) NFKB1CYP2D6LMNABLMNPSR1
Bromide SCHEMBL20742989 0.94 LMNA (0.50) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL14864702 0.86 LMNA (0.44) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL9885888 0.86 LMNA (0.46) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL15065508 0.86 LMNA (0.65) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL8262546 0.86 LMNA (0.65) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL19723211 0.84 ACHE (0.41) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL8928213 0.84 LMNA (0.39) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL20763733 0.83 LMNA (0.48) NFKB1CYP2D6LMNABLMNPSR1
SCHEMBL25163063 0.83 LMNA (0.38) NFKB1CYP2D6LMNABLMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11471537-B2 Oligomer extended insulin-Fc conjugates NOVO NORDISK A/S (DK) 2022-10-18 US disclosed
US-20200261595-A1 Oligomer Extended Insulin-FC Conjugates NOVO NORDISK A/S (DK) 2020-08-20 US disclosed
EP-3606560-A2 OLIGOMER EXTENDED INSULIN-FC CONJUGATES Novo Nordisk A/S (DK) 2020-02-12 EP disclosed
CN-110505885-A Oligomer-extended insulin-Fc conjugates NOVO NORDISK AS 2019-11-26 CN disclosed
WO-2018185131-A2 OLIGOMER EXTENDED INSULIN-FC CONJUGATES NOVO NORDISK A/S (DK) 2018-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261595-A1 Oligomer Extended Insulin-FC Conjugates IAPP, IDE, INSR NFKB1 2053/4885CYP2D6 3299/4885LMNA 4291/4885
US-11471537-B2 Oligomer extended insulin-Fc conjugates IAPP, IDE, INSR NFKB1 2053/4885CYP2D6 3299/4885LMNA 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.